Amphastar Pharmaceuticals’ (AMPH) Hold Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reiterated their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $22.00 price target on the stock, down from their prior price target of $30.00.

Other equities research analysts have also issued research reports about the company. Barclays cut their target price on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 8th. Weiss Ratings downgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, Needham & Company LLC cut their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $27.43.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $21.01 on Tuesday. The company has a market capitalization of $935.58 million, a PE ratio of 10.35, a P/E/G ratio of 1.75 and a beta of 0.92. The company has a quick ratio of 2.90, a current ratio of 4.02 and a debt-to-equity ratio of 0.77. Amphastar Pharmaceuticals has a twelve month low of $17.03 and a twelve month high of $31.26. The firm has a fifty day simple moving average of $21.73 and a 200 day simple moving average of $24.68.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. The firm had revenue of $183.11 million for the quarter, compared to the consensus estimate of $190.48 million. On average, sell-side analysts forecast that Amphastar Pharmaceuticals will post 2.84 EPS for the current year.

Institutional Trading of Amphastar Pharmaceuticals

Several large investors have recently made changes to their positions in AMPH. AQR Capital Management LLC raised its stake in Amphastar Pharmaceuticals by 82.0% during the 1st quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after buying an additional 24,167 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after acquiring an additional 613 shares during the period. Intech Investment Management LLC grew its stake in Amphastar Pharmaceuticals by 43.0% in the first quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock valued at $1,748,000 after acquiring an additional 18,133 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $1,865,000. Finally, Invesco Ltd. increased its holdings in shares of Amphastar Pharmaceuticals by 7.7% during the second quarter. Invesco Ltd. now owns 386,971 shares of the company’s stock valued at $8,885,000 after acquiring an additional 27,828 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.